top of page
news and events
Accession Therapeutics doses first patient in Phase 1 clinical trial of TROCEPT-01 (ATTR-01), a novel cancer immunotherapy
Accession Therapeutics Limited, a biopharmaceutical company developing next generation cancer immunotherapies, today announced it has dosed the first patient in its Phase I clinical trial evaluating TROCEPT-01 (ATTR-01), the company’s lead drug candidate from its proprietary TROCEPT platform technology.
1 day ago
Accession Therapeutics presents first-in-human ATTEST trial at the European Society for Medical Oncology (ESMO) Congress 2025
At the ESMO Congress 2025, taking place between 17-21 October, Accession Therapeutics are sharing details of our ATTEST study, a first-in-human Phase 1 trial of ATTR-01 (TROCEPT-01) in patients with selected epithelial tumours.
Oct 17
Five Abstracts Accepted at ESMO, SITC, and CICON 2025
Accession Therapeutics is pleased to announce that five abstracts showcasing the company’s TROCEPT cancer immunotherapy platform have been accepted for presentation at three leading international oncology conferences in 2025.
Sep 8
Accession Therapeutics obtains approval for first TROCEPT cancer clinical trial in UK
Accession Therapeutics obtains approval for first TROCEPT cancer clinical trial in UK
Jan 30
Accession Therapeutics submits CTA to the UK MHRA to start Phase 1 first-in-human clinical trial with lead TROCEPT anti-cancer immunotherapy
Milestone reached in under three years from company inception
Sep 4, 2024
Accession Therapeutics raises £25m to fund company through generation of first clinical data & to advance second candidate
Accession Therapeutics raises £25m to fund company through generation of first clinical data & to advance second candidate
Apr 25, 2024
bottom of page